Medaphor Group PLC Pilot of ultrasound AI software for pregnancy scan (5159E)
February 12 2018 - 1:00AM
UK Regulatory
TIDMMED
RNS Number : 5159E
Medaphor Group PLC
12 February 2018
MedaPhor Group plc
("MedaPhor" or the "Group" or the "Company")
Pilot of ultrasound AI software for pregnancy screening
ScanNav real-time image analysis software to be piloted by St
George's, London
MedaPhor Group plc (AIM: MED), the intelligent ultrasound
software and simulation company, announces the first pilot of its
ScanNav real-time image analysis software at the Fetal Medicine
Department of St George's University Hospitals NHS Trust, London,
U.K.
ScanNav is believed to be the first CE marked artificial
intelligence (AI) system to carry out an automated, real-time "peer
review" of obstetric ultrasound images as the patient is
scanned.
Monitoring performance by manually auditing images
retrospectively is very time consuming, so ScanNav instead supports
clinical staff by instantly confirming that the images they save
conform to protocol, meaning additional images can be taken
straight away if required.
Initially targeted at the U.K. pregnancy screening programme
(offered to all women at 20 weeks of pregnancy), ScanNav evaluates
over 50 individual criteria to verify that the six views required
by the NHS Fetal Anomaly Screening Programme are complete and fit
for purpose.
ScanNav uses deep learning technology to assess the same
features that sonographers look for in ultrasound images. The
system has "learnt" this using over 350,000 images that were
assessed by a panel of senior sonographers. Initial validation
studies have shown the AI system is as good as an expert colleague
in providing peer review.
Commenting on their interest in ScanNav, Katy Cook, Lead
Sonographer in St George's Hospital Fetal Medicine Department,
said: "Newly qualified sonographers, or those in training, may find
this particularly helpful, giving confidence and enhancing skills
to attain excellent imaging techniques. This AI software could also
potentially automate the required auditing for obstetric scanning
and demonstrate quality and competency for every sonographer in a
busy clinical setting. This new way of assessing images looks very
interesting and could have great potential."
Commenting on the evaluation, Nick Sleep, Chief Technology
Officer of MedaPhor, said: "We are very grateful to Katy Cook and
her team at St George's for their feedback during this pilot.
Understanding how ScanNav is utilised by expert sonographers in a
clinical environment is helping us to better determine how our
proposed range of ScanNav products will fit into the workflow of a
busy fetal medicine department and support sonographers and doctors
in ultrasound scanning."
Enquiries:
MedaPhor Group plc www.medaphor.com
Stuart Gall, CEO Tel: +44 (0)29 2075
Nick Sleep, CTO 6534
Cenkos Securities Tel: +44 (0)20 7397
8900
Camilla Hume/Bobbie Hilliam
(Nominated Advisor)
Michael Johnson / Julian
Morse (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or
medaphor@walbrookpr.com
Paul McManus / Anna Mob: +44 (0)7980 541 893 / Mob:
Dunphy +44 (0)7876 741 001
About MedaPhor (www.medaphor.com)
MedaPhor (AIM: MED), the intelligent ultrasound software and
simulation company, develops artificial intelligence-based clinical
image analysis software tools, augmented reality-based needle
guidance software and advanced hi-fidelity haptic and manikin-based
training simulators for medical practitioners.
Based in Cardiff and Oxford in the UK and Atlanta in the US,
MedaPhor is split into two divisions:
Intelligent Ultrasound Simulation and Training
Focuses on hi-fidelity ultrasound education and training through
simulation. Its two main products are the ScanTrainer OBGYN and
General Medical simulator training platform and the HeartWorks
echocardiography simulator platform. Over 500 MedaPhor simulators
have been sold to over 300 medical institutions in over 30
countries around the world.
Intelligent Ultrasound Clinical Support
Focuses on augmented reality and deep-learning based algorithms
to make ultrasound machines smarter and more accessible. Products
in development include ScanNav which uses machine-learning based
algorithms to automatically identify and grade ultrasound images to
provide scan assessment and audit of obstetric scanning.
NeedleGuide aims to simplify ultrasound-guided needling by using
deep learning and augmented reality to provide the user with
pathway guidance and automated tracking for a range of medical
procedures.
Some products in the pipeline may require US FDA approval, as
such this material should be considered informational only and does
not constitute an offer to sell, or infer claims or benefits.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGGUCPPUPRUBU
(END) Dow Jones Newswires
February 12, 2018 02:00 ET (07:00 GMT)
Intelligent Ultrasound (LSE:IUG)
Historical Stock Chart
From Apr 2024 to May 2024
Intelligent Ultrasound (LSE:IUG)
Historical Stock Chart
From May 2023 to May 2024